Capstone to wind down operations after failing to partner dermal scarring product
This article was originally published in Scrip
Executive Summary
In its next move to wind down operations, Capstone Therapeutics is to stop the clinical development of its principal drug candidate as well as halting activities relating to a second compound. The company has also reduced the size of its board of directors by half.